Specifying stroke

Thrombolytic Science targeting ischemic stroke with combination product TS01

Thrombolytic Science International LLC is developing a combination product to target only the clots that lead to stroke, which it expects will significantly reduce bleeding and potentially double the treatment window compared with the only drug approved for the indication.

The company, which was founded in 2006 but emerged from stealth mode in January, is developing a mutated version of pro-urokinase. Urokinase is a serine protease that activates plasminogen to start the proteolysis cascade, leading to clot thrombolysis.

Because

Read the full 770 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE